Non-addictive poppy-derived analgesic
Pain Management
Pre-clinicalActive
Key Facts
About Emerzene
Emerzene is a private, pre-clinical biotech firm pioneering a novel approach to non-addictive pain management. Its core innovation involves using CRISPR gene editing to develop a proprietary, perennial strain of poppy (P. bracteatum) that produces therapeutic alkaloids without morphine, thereby eliminating the addictive potential of traditional opioids. The company employs a vertically integrated model, controlling cultivation, a proprietary water-based extraction process, and API production. Emerzene's mission is to supply effective pain relief without addiction risk, positioning itself as a potential disruptor in the multi-billion-dollar pain management market.
View full company profileTherapeutic Areas
Other Pain Management Drugs
| Drug | Company | Phase |
|---|---|---|
| Authorized Generic of Nucynta® ER (tapentadol) | hikma | Launched |
| Authorized Generic of Nucynta® (tapentadol) | hikma | Launched |
| Intradermal Microneedle Patch | Isosceles Pharmaceuticals | Pre-clinical |
| LymphaTouch Device | Lymphatouch | Commercial |
| Generic Oxycodone ER (Oxycontin) | Natco Pharma | Launched |
| Generic Tapentadol ER | Hikma Pharmaceuticals | Approved |
| Generic Tapentadol | Hikma Pharmaceuticals | Approved |